Speculator makes case for candidates to end years of hurt for stem cell investors

31 July 2017
2019_biotech_test_vial_discovery_big

Most early stage stem cell investors have lost their shirts, admits a market commentator as it puts forward the case for investment in a handful or current biotech companies that might be worth a punt.

Microcap Speculators, which provides reports, company profiles and other investor relations materials, has published a commentary on these companies and the wider area of research, entitled The Big Deal About Stem Cell Therapies and Regenerative Medicine.

"The dot-com like era of regenerative medicine is over. Investors will need to look at companies solving issues with stem cells or those taking a completely new approach"

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology